Experts discuss the challenges of treating wet age-related macular degeneration (AMD) with current anti-VEGF therapies and emphasize the need for more durable treatment options. The conversation highlights the potential for advancements that could significantly improve patient outcomes.
In this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami Health System and Bascom Palmer Eye Institute, and Wesley Jackson, chief science officer at Valitor. We talk about the eye condition call wet age-related macular degeneration (AMD), the limits of anti‑VEGF therapy and the push for true durability to change a patient’s life.
Original title: “When vision fades: Rethinking wet AMD and the durability gap”